🇺🇸 FDA

Intelligence Platform

Patents

Browse 16 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12331099

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11732024

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084865

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066458

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10464992

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400025

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914763

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9580489

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340594

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802107

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8481046

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8420619

Rescue of photoreceptors by intravitreal administration of an expression vector encoding a

Ceregene, Inc. · Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8242093

Rescue of photoreceptors by intravitreal administration of an expression vector encoding a

Ceregene, Inc. · Granted Tue Aug 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8092803

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7807164

Lyophilized VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 05 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7608261

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted